EPR or no EPR? The billion-dollar question
Abstract
The enhanced permeability effect is shown to be dependent on tumor histology in canine spontaneous tumors.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Today, the EPR remains a controversial topic in nanomedicine.
“Today, the EPR remains a controversial topic in nanomedicine [152].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [152]
Cited by
Sorted by citations
Bright quantum dots emitting at ∼1,600 nm in the NIR-IIb window for deep tissue fluorescence imaging
Zhang, M., Yue, J., Cui, R., Ma, Z., Wan, H., Wang, F., Zhu, S., Zhou, Y., Kuang, Y., Zhong, Y., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1806153115 · Cited by 432 · see citing works
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330 · see citing works
Evolution of macromolecular complexity in drug delivery systems
Kakkar, A. K., Traverso, G., Farokhzad, O. C., Weissleder, R., & Langer, R. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0063 · Cited by 325 · see citing works
Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 301 · see citing works
“tumor types and is not observed for all solid tumors [140, 141].”
Enhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives
Vagena, I.-A., Malapani, C., Gatou, Μ.-A., Lаgopati, N., & Pavlatou, E. A. (2025) · Applied Sciences · doi:10.3390/app15063189 · Cited by 232 · see citing works
Drug Delivery Systems Based on Poly(2‐Oxazoline)s and Poly(2‐Oxazine)s
Sedláček, O., & Hoogenboom, R. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900168 · Cited by 130 · see citing works
Investigating the EPR effect of nanomedicines in human renal tumors via ex vivo perfusion strategy
Ding, Y., Xu, Y., Yang, W., Niu, P., Li, X., Chen, Y., Li, Z., Liu, Y., An, Y., Liu, Y., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100970 · Cited by 127 · see citing works
Challenges and opportunities for siRNA-based cancer treatment
Wang, T., Shigdar, S. L., Shamaileh, H. A., Gantier, M. P., Yin, W., Xiang, D., Wang, L., Zhou, S.-F., Hou, Y., Wang, P., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.045 · Cited by 123 · see citing works
Current developments in nanotechnology for improved cancer treatment, focusing on tumor hypoxia
Phung, C. D., Tran, T. H., Pham, L. M., Nguyen, H. T., Jeong, J., Yong, C. S., & Kim, J. O. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.029 · Cited by 115 · see citing works
Combination therapy based on nano codelivery for overcoming cancer drug resistance
Wang, H., & Huang, Y. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100024 · Cited by 115 · see citing works
From 2D to 3D Cancer Cell Models—The Enigmas of Drug Delivery Research
Zundert, I. V., Fortuni, B., & Rocha, S. (2020) · Nanomaterials · doi:10.3390/nano10112236 · Cited by 109 · see citing works
Tumor microenvironment-responsive dynamic inorganic nanoassemblies for cancer imaging and treatment
Yang, Y. P., Wu, H., Liu, B., & Liu, Z. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114004 · Cited by 107 · see citing works
Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis
Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030389 · Cited by 98 · see citing works
“Today, the EPR remains a controversial topic in nanomedicine [152].”
BackgroundJohnsen, K. B., Gudbergsson, J. M., Duroux, M. C., Moos, T., Andresen, T. L., & Simonsen, J. B. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.002 · Cited by 95 · see citing works
Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer
Meng, H., & Nel, A. E. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.014 · Cited by 92 · see citing works
α-Amino acid N-carboxyanhydride (NCA)-derived synthetic polypeptides for nucleic acids delivery
Liu, Y., & Yin, L. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.007 · Cited by 87 · see citing works
Eskandari, A., & Suntharalingam, K. (2019) · Chemical Science · doi:10.1039/c9sc01275c · Cited by 77 · see citing works
Targeting strategies for improving the efficacy of nanomedicine in oncology
Villaverde, G., & Baeza, A. (2019) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.10.16 · Cited by 73 · see citing works
Polypeptide‐Based Conjugates as Therapeutics: Opportunities and Challenges
Zagorodko, O., Arroyo‐Crespo, J. J., Nebot, V. J., & Vicent, M. J. (2016) · Macromolecular Bioscience · doi:10.1002/mabi.201600316 · Cited by 67 · see citing works
Aptamers and nanobodies as alternatives to antibodies for ligand-targeted drug delivery in cancer
Sanjanwala, D., & Patravale, V. B. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103550 · Cited by 55 · see citing works
Biologics and their delivery systems: Trends in myocardial infarction
Borrelli, M. A., Turnquist, H. R., & Little, S. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.014 · Cited by 53 · see citing works
Martin, B., Séguin, J., Annereau, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74809-z · Cited by 40 · see citing works
Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology
Baker, A., Ho, A. P. T., Itzhaki, L. S., & Fruk, L. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202503958 · Cited by 44 · see citing works
Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms
Song, W., Das, M., & Chen, X. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.011 · Cited by 37 · see citing works
“The EPR effect was also observed in patients with locally advanced cancers [7], although this effect varies depending on a patient’s pathological and physiological characteristics and clinical condition [8, 9].”
BackgroundNanoparticles for MRI-guided radiation therapy: a review
Smith, L., Byrne, H. L., Waddington, D. E. J., & Kuncic, Z. (2022) · Cancer Nanotechnology · doi:10.1186/s12645-022-00145-8 · Cited by 37 · see citing works
“It is also recognised that the EPR effect is not entirely homogenous and appears to be influenced by factors such as the tumour histological subtype (Wang 2015), size and vascular infiltration (Maeda 2015; Pasut 2019).”
BackgroundAlpha-particle radiotherapy: For large solid tumors diffusion trumps targeting
Zhu, C., Sempkowski, M., Holleran, T. J., Linz, T., Thomas, B., Josefsson, A., Bruchertseifer, F., Morgenstern, A., & Sofou, S. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.03.035 · Cited by 34 · see citing works
Kidney-Targeted Redox Scavenger Therapy Prevents Cisplatin-Induced Acute Kidney Injury
Williams, R. M., Shah, J., Mercer, E., Tian, H. S., Thompson, V., Cheung, J. M., Dorso, M. A., Kubala, J. M., Gudas, L. J., de Stanchina, E., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.790913 · Cited by 37 · see citing works
“We cannot discount, however, the possibility that some nanoparticle accumulation in the tumors may occur via the enhanced permeability and retention effect (EPR) and cause a reduction in cisplatin antitumor efficacy (Matsumura and Maeda, 1986; Sugihara and Gemba, 1986; Bertrand et al., 2014; Wang, 2015).”
BackgroundChemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system
Bolaender, A., Zatorska, D., He, H., Joshi, S., Sharma, S., Digwal, C. S., Patel, H. J., Sun, W., Imber, B. S., Ochiana, S. O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24821-2 · Cited by 35 · see citing works
Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations
Tetterton-Kellner, J., Jensen, B. C., & Nguyen, J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115361 · Cited by 32 · see citing works
Exploring the current landscape of chitosan-based hybrid nanoplatforms as cancer theragnostic
Nair, R., Paul, P., Maji, I., Gupta, U., Mahajan, S., Aalhate, M., Guru, S. K., & Singh, P. K. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.121644 · Cited by 33 · see citing works
Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer
Lu, T., & Prakash, J. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s279192 · Cited by 26 · see citing works
Xue, F., Dixon, H., Glen‐Ravenhill, H., Karaosmanoglu, S., Li, Q., Yan, L., & Chen, X. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900093 · Cited by 26 · see citing works
Stras, S., Howe, A. K., Prasad, A. G., Salerno, D., Bhatavdekar, O., & Sofou, S. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00812 · Cited by 24 · see citing works
Versatile and Robust Method for Antibody Conjugation to Nanoparticles with High Targeting Efficiency
Zundert, I. V., Bravo, M., Deschaume, O., Cybulski, P., Bartic, C., Hofkens, J., Uji‐i, H., Fortuni, B., & Rocha, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122153 · Cited by 23 · see citing works
Jones, S. K., Douglas, K. A., Shields, A. F., & Merkel, O. M. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.06.014 · Cited by 13 · see citing works
Tsolaki, E., Doran, W., Overbeck, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.29.067660 · Cited by 7 · see citing works
Passeri, G., Vincent, R. A., Xiao, Z., Northcote‐Smith, J., & Suntharalingam, K. (2022) · ChemMedChem · doi:10.1002/cmdc.202200599 · Cited by 7 · see citing works
Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology
Baker, A., Ho, A. P. T., Itzhaki, L. S., & Fruk, L. (2025) · Angewandte Chemie · doi:10.1002/ange.202503958 · Cited by 3 · see citing works
Silicasomes in Oncology: From Conventional Chemotherapy to Combined Immunotherapy
Arroyo-Nogales, A., Plaza-Palomo, G., Gónzalez‐Larre, J., Jiménez‐Falcao, S., & Baeza, A. (2025) · Molecules · doi:10.3390/molecules30061257 · Cited by 4 · see citing works
“Therefore, the conventional dogma of the suitability to employ nanometric carriers to deliver chemotherapy has been subject to intense debate [9].”
Nanotechnology for Bioengineers
Zhang, W. (2020) · Synthesis lectures on biomedical engineering · doi:10.1007/978-3-031-01668-4 · Cited by 1 · see citing works
Belfiore, L. (2019) · Research Online (University of Wollongong)
Nanotechnology for Bioengineers
Zhang, W. (2020) · Synthesis lectures on biomedical engineering · doi:10.2200/s01031ed1v01y202007bme060
Nanomaterial-Based Contrast and Therapeutic Agents
Ramesh, S. S. R., Patra, P., & Rengan, A. K. (2025) · Springer eBooks · doi:10.1007/978-981-95-0938-6_10
- Authors
- Wang, A. Z.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Wang, Andrew Z.
- ORCID
- Wang, Andrew Z.
- Venue
- Science Translational Medicine
- Published
- 2015-07
- Volume
- 7
- Issue
- 294
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W1916878682
- Cited by
- 44
- References
- 0
- Citations by year
- 2025: 5 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 5 · 2020: 10 · 2019: 6 · 2018: 4 · 2017: 4 · 2016: 2
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Veterinary Oncology Research
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- enhanced permeability and retention effect, tumor histology, tumor vascular permeability, tumor microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
